TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Improving Rhode Island's Tuberculosis Preventive Services in Primary Care

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* \> 18 years of age~* Primary care team members in Rhode Island including doctors, nurses, nurse practitioners, physician assistants, or other healthcare providers who are involved in primary care.~Exclusion Criteria:~* \< 18 years of age~* Primary care team members who do not primarily work in Rhode Island

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Qualitative (Type: NO_INTERVENTION): Specific Aim 1: Explore the specific knowledge, attitudinal, and skills gaps to TB infection testing and treatment among primary care team members in RI through qualitative key informant interviews.~In Aim 1, 25 primary care team members from the Brown Family Medicine and Care New England networks will be purposively sampled to undergo key informant interviews regarding TB infection testing and treatment knowledge, attitudinal, and skill gaps. Questions will be asked to ascertain gaps throughout the entire latent TB infection care cascade. The results from Aim 1 will be used to design the survey instrument and the curriculum for an innovative, telementoring program (TB infection ECHO).
- Quantitative (Type: OTHER): Specific Aim 2: Design and evaluate an evidence-based telementoring intervention (ECHO model) that addresses the identified TB infection gaps in Aim 1, and evaluate this model for feasibility as well as its impact on primary care team member knowledge and TB infection testing and treatment in RI. 12 primary care team members will be recruited to participate in a virtual six-month TB infection ECHO course. Participants will be asked to complete quantitative surveys before and after the course as well as post-session surveys following each session. Survey questions will assess feasibility measures related to process, resources, and management and impact measures related to learning and performance. Paired data from pre- and post-course surveys will be analyzed accordingly depending on the distribution of results.
- Retrospective chart review (Type: OTHER): Pilot a retrospective electronic medical record (EMR) data review to examine RI primary care providers' testing and treatment before and after ECHO implementation and evaluate the model's reach. In Aim 3, data will be retrospectively extracted from two participants' clinics to research RI primary care providers' testing and treatment patterns before and after the ECHO course. The two clinics will be identified once Aim 2 is completed.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Association Between Decreasing Labor Analgesia Epidural Infusion and Forceps Delivery

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Singletons~* Viable fetal vaginal deliveries between January 2004-October 2005~Exclusion Criteria:~* Outside specified time frame~* Multiparity~* Fetal demise

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: t

Study Arms:
- Instrumental Vaginal Delivery (IVD) (Type: None): Instrumental vaginal delivery (IVD) is attempted to prevent fetal hypoxia if the second stage of labor is prolonged. It includes forceps and vacuum extractions.
- Spontaneous Vaginal Delivery (SVD) (Type: None): The control group consisted of parturients who had a spontaneous vaginal delivery (SVD)in the same 24 hour period who were case-matched for gravidity and parity.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Topical Antibiotic Prophylaxis for Eyelids

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Patients aged 18 and older who are undergoing various eyelid procedures in an office, ambulatory care center, or operating room including but not limited to:~* blepharoplasty (upper and lower lids);~* ectropion repair;~* entropion repair;~* external dacryocystorhinostomy;~* external levator resection;~* eyelid lesion removal and/or biopsy;~* eyelid reconstruction and defect repair including after Mohs surgery;~* fat pad excision (upper and lower lids);~* gold or platinum weight implantation;~* internal levator resection;~* lateral tarsal strip;~* orbital fracture repair requiring periorbital incisions;~* orbitotomy requiring periorbital incisions;~* tarsorrhaphy;~* wedge excision.~* Patients undergoing repeat procedures will also be included.~Exclusion Criteria:~* Patients aged younger than 18 years old who are undergoing the above eyelid procedures in an office, ambulatory care centers, operating rooms;~* patients undergoing chalazion removal;~* patients who have had previous wound infections at the site of the procedure;~* patients with oral or IV antibiotic use within 10 days prior to procedure;~* patients requiring IV antibiotics during the procedure;~* patients with grossly contaminated or inflamed wounds;~* patients with human or animal bites, patients with wounds resulting from trauma~* patients allergic to all study drug options.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Topical Antibiotic Ointment (Type: EXPERIMENTAL): Intervention: 200 patients in the antibiotic arm will receive either erythromycin or bacitracin, based on allergies, surgeon preference, and antibiotic availability. If neither antibiotic is obtainable by the patient, bacitracin polymyxin will be prescribed instead. Antibiotic ointment is to be applied to the surgical incision(s) 4 times daily for 1 week.
- Topical Non-Antibiotic Ointment (Type: PLACEBO_COMPARATOR): Intervention: 200 patients in the placebo group will receive mineral oil/petrolatum-based artificial tear ointment to be applied to the surgical incision(s) 4 times daily for 1 week.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Acute Airway Vascular Smooth Muscle Effects of Inhaled Budesonide

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~Twenty lifetime nonsmokers moderate or severe asthmatics; FEV1≥50 of predicted on the screening day~Exclusion Criteria:~Women of childbearing potential who do not use accepted birth control measures; pregnant and breast feeding women; Cardiovascular disease and/or use of cardiovascular medication; Subjects with known beta-adrenergic agonist or glucocorticosteroid intolerance; Acute respiratory infection and or acute exacerbation of asthma within four weeks prior to the study; Use of systemic glucocorticosteroids within 4 weeks prior to the study; Daily ICS dose (fluticasone or budesonide) \> 500ug; Diabetes mellitus

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- budesonide 360ug (Type: EXPERIMENTAL): asthmatic subject received different doses of inhaled budesonide in random other
- budesonide 720ug (Type: EXPERIMENTAL): asthmatic subject received different doses of inhaled budesonide in random other
- budesonide 1440ug (Type: EXPERIMENTAL): asthmatic subject received different doses of inhaled budesonide in random other
- placebo (Type: PLACEBO_COMPARATOR): asthmatic subject received inhaled placebo
- Budesonide720ug 4 times (Type: EXPERIMENTAL): asthmatic subject received 720ug of inhaled budesonide 4 times separated by 30 minutes.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Ezetimibe (SCH 58235) Taken With Either Atorvastatin or Simvastatin in Participants With Familial Hypercholesterolemia (MK-0653-018)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* With a diagnosis of homozygous familial hypercholesterolemia~* All females must have a negative pregnancy test prior to study entry. Women of child bearing potential must agree to practice an effective barrier method of birth control for the duration of the study, until one month after treatment.~* Postmenopausal women who are receiving postmenopausal hormonal therapy or raloxifene must be maintained on a stable estrogen (ERT), estrogen/progestin (HRT) or raloxifene regimen during the study period. ERT, HRT or raloxifene cannot be changed during study period.~* Must follow prescribed or stricter diet, and demonstrate completion of Diet Diaries~Exclusion Criteria:~* A history of mental instability, drug or alcohol abuse; or have been treated or are being treated for severe psychiatric illness which, in the opinion of the Investigator, may interfere with optimal participation in the study.~* With underlying disease likely to limit life span to less than 1 year.~* Have previously been randomized in any studies examining ezetimibe~* Pregnant or lactating women.~* With known hypersensitivity or any contraindication to statin therapy.

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Atorvastatin 80 mg (Type: EXPERIMENTAL): 80 mg atorvastatin taken orally, once daily for 12 weeks
- Ezetimibe + Atorvastatin 40 mg (Type: EXPERIMENTAL): 10 mg ezetimibe and 40 mg atorvastatin taken orally, once daily for 12 weeks
- Ezetimibe + Atorvastatin 80 mg (Type: EXPERIMENTAL): 10 mg ezetimibe and 80 mg atorvastatin taken orally, once daily for 12 weeks
- Simvastatin 80 mg (Type: EXPERIMENTAL): 80 mg simvastatin taken orally, once daily for 12 weeks
- Ezetimibe + Simvastatin 40 mg (Type: EXPERIMENTAL): 10 mg ezetimibe and 40 mg simvastatin taken orally, once daily for 12 weeks
- Ezetimibe + Simvastatin 80 mg (Type: EXPERIMENTAL): 10 mg ezetimibe and 80 mg simvastatin taken orally, once daily for 12 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Multi-centre Randomized Double Blind 52-week Study to Assess the Safety of QVA149 Compared to QAB149 in Patients With COPD Who Have Moderate to Severe Airflow Limitation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Male and female adults aged ≥40 years~* Patients with stable COPD according to GOLD strategy (GOLD 2011).~* Patients with airflow limitation indicated by a post-bronchodilator FEV1 ≥ 30% and \<80% of the predicted normal, and a post-bronchodilator FEV1/FVC \< 0.70.~* Current or ex-smokers who have a smoking history of at least 10 pack years.~* Patients with an mMRC ≥ grade 2~Exclusion Criteria:~* History of long QT syndrome or prolonged QTc~* Patients who have had a COPD exacerbation that required treatment with antibiotics and/or systemic corticosteroids and/or hospitalization in the 6 weeks prior to Visit 1.~* Patients with Type I or uncontrolled Type II diabetes~* Patients with a history of asthma or have concomitant pulmonary disease~* Patients with paroxysmal (e.g. intermittent) atrial fibrillation. Only patients with persistent atrial fibrillation and controlled with a rate control strategy for at least six months could be eligible~* Patients who have clinically significant renal, cardiovascular, neurological, endocrine, immunological, psychiatric, gastrointestinal, hepatic, or hematological abnormalities which could interfere with the assessment of safety~* Other protocol defined inclusion/exclusion criteria may apply

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- QVA149 dose 1 (Type: EXPERIMENTAL): QVA149 27.5/12.5 μg capsules
- QVA149 dose 2 (Type: EXPERIMENTAL): QVA149 27.5/25 μg capsules
- QAB149 (Type: ACTIVE_COMPARATOR): QAB149 75 μg capsules

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Itch Relieving Effect of Botox: a Study in Healthy Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Healthy volunteers between 18 and 50 years of age.~2. Must be in general good health with no disease or physical conditions that would impair evaluation of itch and pain perception.~3. No history of chronic itch or pain.~4. Must abstain from the use of any systemic or topical anti-histamine, steroid, or pain relief medications from the week prior to the study till the completion of the study.~5. Must abstain from the use of moisturizers on the arm.~Exclusion Criteria:~1. Individuals under 18 or over 50 years of age.~2. Inability to complete the required measures.~3. The presence of an itchy skin disease.~4. Diagnosis of diseased that would affect itch or pain perception (e.g. neuropathies).~5. Currently enrolled in any investigational study in which the subject is receiving any type of drug, biological, or non-drug therapy.~6. Use of oral, topical analgesics, or other medications known to interfere with itch or pain perception in the week prior to the study and throughout the study (e.g. antihistamines, anesthetics, opioids, neuroleptics, etc.).~7. Use of emollients on the arms a week prior to the study and throughout the study.~8. Use of anti-depressants, anti-psychotics, and illicit drugs.~9. Known history of neuropathy, uremia, uncontrolled thyroid disease, and diabetes mellitus.~10. Use of Botulinum toxin in the last year.~11. Known allergies to Botox.~12. Pregnant women. (Women of child bearing potential will undergo an human chorionic gonadotrophin (hCG) pregnancy test before Botox application).~13. Hypersensitivity to any botulinum toxin preparation or to any of the components in the formulation.~14. Infection at the injection site.~15. Cardiovascular disease.~16. Neuromuscular disorder (e.g., amyotrophic lateral sclerosis, myasthenia gravis, or Lambert-Eaton syndrome).~17. Compromised respiratory function.~18. Dysphagia.~19. History of urinary tract infection.~20. History of urinary retention.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: t

Study Arms:
- Botox (Type: EXPERIMENTAL): 10 units of Botox intradermally injected into one forearm. The subject is blinded to which forearm receives the Botox and which forearm receives the saline vehicle.
- Saline (Type: PLACEBO_COMPARATOR): Saline vehicle intradermally injected into the other forearm. The subject is blinded to which forearm receives the Botox and which forearm receives the saline vehicle.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Defective Atypical Protein Kinase C (PKC) Activation in Diabetes and Metabolic Syndrome

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: CROSS_SECTIONAL
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Stable uncomplicated type 2 diabetes~* Able to be off oral treatments for 2 months~Exclusion Criteria:~* Diabetic complications related to heart, eye, nerve problems~* Renal impairment~* Cardiovascular disease~* Hepatic disease~* Prior history of other disorders or complications caused by diseases~* Insulin therapy needed

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: t

Study Arms:
- Group 1 (Type: None): type 2 diabetic individuals
- Group 2 (Type: None): type 1 diabetic individuals or those with diabetes secondary to pancreatic disease
- Group 3 (Type: None): non-diabetic individuals who are not considered to be overweight
- Group 4 (Type: None): non-diabetic individuals who are considered to be overweight
- Group 5 (Type: None): non-diabetic and type 2 diabetic individuals who will be subjected to an exercise study
- Group 6 (Type: None): individuals who have or are suspected of having glucose intolerance, including patients who have a history of gestational diabetes and patients who have polycystic ovary syndrome
- Group 7 (Type: None): healthy non-diabetic subjects who will receive one dose of metformin orally 1-2 hours before performing procedures

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: MAGNETISMM-2: Study of Elranatamab (PF-06863135) in Japanese Participants With Multiple Myeloma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of multiple myeloma (IMWG criteria)~* Measurable disease, as defined by at least 1 of the following~  1. Serum myeloma (M) protein ≥0.5 g/dL (5 g/L)~ 2. Urine M protein ≥200 mg/24 h~ 3. Serum free light chain (FLC) \>100 mg/L (10 mg/dL) with abnormal kappa:lambda ratio~* Participants must have progressed on or been intolerant of at least 3 prior therapies including proteasome inhibitor, IMID drug and anti-CD38 antibody, either in combination or as a single agent~* ECOG PS 0, 1 or 2. PS 3 is permitted if PS is due solely to bone pain~* Adequate bone marrow, hematological, kidney and liver function~* Resolved acute effects of any prior therapy to baseline severity or CTCAE Grade 1~* Not pregnant and willing to use contraception~Exclusion Criteria:~* POEMS syndrome~* Any other active malignancy within 3 years prior to enrollment, except for adequately treated basal cell or squamous cell skin cancer, or carcinoma in situ~* History of active autoimmune disorders~* Any form of primary immunodeficiency~* History of severe immune-mediated adverse event with prior immunomodulatory treatment~* Stem cell transplant within 12 weeks prior to enrollment~* Active graft versus host disease other than Grade 1 skin involvement, or that requiring immunosuppressive treatment~* Requirement for systemic immune suppressive medication~* Active, uncontrolled bacterial, fungal, or viral infection, including HBV, HCV, known HIV or AIDS related illness and SARS-CoV2~* Previous administration with an investigational drug within 4 weeks or 5 half-lives preceding the first dose of study intervention used in this study (whichever is longer)~* Known or suspected hypersensitivity to component of elranatamab (PF-06863135), murine and bovine products~* Live attenuated vaccine within 4 weeks

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Elranatamab (PF-06863135) (Type: EXPERIMENTAL): BCMA-CD3 bispecific antibody

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Outcomes of Stem Cells for Cerebral Palsy

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Cerebral palsy of any types caused by oxygen deprivation.~Exclusion Criteria:~* Epilepsy~* Hydrocephalus with ventricular drain~* Coagulation disorders~* Allergy to anesthetic agents~* Severe health conditions such as cancer, failure of heart, lung, liver or kidney~* Active infections

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 15 Years
- Healthy Volunteers: f

Study Arms:
- Stem cell transplantation (Type: EXPERIMENTAL): 2 intrathecal administrations of autologous bone marrow mononuclear cells at baseline and 3 months afterward

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete